Log in
NASDAQ:LOGC

LogicBio Therapeutics Stock Forecast, Price & News

$7.00
0.00 (0.00 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$6.92
Now: $7.00
$7.75
50-Day Range
$5.41
MA: $6.99
$8.75
52-Week Range
$3.05
Now: $7.00
$11.60
Volume648,141 shs
Average Volume78,049 shs
Market Capitalization$165.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.33
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LOGC
CUSIPN/A
CIKN/A
Phone617-245-0399

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.84 per share

Profitability

Net Income$-40,130,000.00

Miscellaneous

Employees23
Market Cap$165.49 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$7.00
0.00 (0.00 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LOGC News and Ratings via Email

Sign-up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











LogicBio Therapeutics (NASDAQ:LOGC) Frequently Asked Questions

How has LogicBio Therapeutics' stock been impacted by Coronavirus?

LogicBio Therapeutics' stock was trading at $7.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, LOGC shares have decreased by 0.6% and is now trading at $7.00.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of LogicBio Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for LogicBio Therapeutics
.

When is LogicBio Therapeutics' next earnings date?

LogicBio Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for LogicBio Therapeutics
.

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics Inc (NASDAQ:LOGC) issued its quarterly earnings data on Monday, August, 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.48) by $0.13.
View LogicBio Therapeutics' earnings history
.

What price target have analysts set for LOGC?

2 analysts have issued twelve-month target prices for LogicBio Therapeutics' shares. Their forecasts range from $20.00 to $20.00. On average, they expect LogicBio Therapeutics' share price to reach $20.00 in the next twelve months. This suggests a possible upside of 185.7% from the stock's current price.
View analysts' price targets for LogicBio Therapeutics
.

Who are some of LogicBio Therapeutics' key competitors?

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Stoke Therapeutics (STOK), Alector (ALEC), Acceleron Pharma (XLRN), Homology Medicines (FIXX), II-VI (IIVI), Micron Technology (MU) and Precision BioSciences (DTIL).

Who are LogicBio Therapeutics' key executives?

LogicBio Therapeutics' management team includes the following people:
  • Mr. Frederic Chereau, Pres, CEO & Director (Age 52)
  • Mr. Matthias B. Jaffé, Chief Financial Officer (Age 50)
  • Mr. Tom Wilton, Chief Bus. Officer (Age 45)
  • Dr. Leszek Lisowski Ph.D., Co-Founder
  • Dr. Adi Barzel, Co-Founder

When did LogicBio Therapeutics IPO?

(LOGC) raised $77 million in an initial public offering on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

What is LogicBio Therapeutics' stock symbol?

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

Who are LogicBio Therapeutics' major shareholders?

LogicBio Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bridgeway Capital Management Inc. (0.54%), Goldman Sachs Group Inc. (0.17%), Nuveen Asset Management LLC (0.12%), Bank of New York Mellon Corp (0.12%), Charles Schwab Investment Management Inc. (0.11%) and First Trust Advisors LP (0.06%).
View institutional ownership trends for LogicBio Therapeutics
.

Which major investors are buying LogicBio Therapeutics stock?

LOGC stock was purchased by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Goldman Sachs Group Inc., Jacobs Levy Equity Management Inc., Nuveen Asset Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., American International Group Inc., and Bank of America Corp DE.
View insider buying and selling activity for LogicBio Therapeutics
.

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is LogicBio Therapeutics' stock price today?

One share of LOGC stock can currently be purchased for approximately $7.00.

How big of a company is LogicBio Therapeutics?

LogicBio Therapeutics has a market capitalization of $165.49 million. The company earns $-40,130,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. LogicBio Therapeutics employs 23 workers across the globe.

What is LogicBio Therapeutics' official website?

The official website for LogicBio Therapeutics is www.logicbio.com.

How can I contact LogicBio Therapeutics?

LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The company can be reached via phone at 617-245-0399 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.